DUL:F:F-Alnylam Pharmaceuticals Inc (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 250

Change

0.00 (0.00)%

Market Cap

USD 27.60B

Volume

25.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOV:F Novo Nordisk A/S

N/A

USD 526.04B
NOVA:F Novo Nordisk A/S

N/A

USD 524.27B
RGO:F Regeneron Pharmaceuticals Inc

N/A

USD 117.89B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 91.04B
CSJ:F CSL Limited

N/A

USD 91.04B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 31.06B
1AE:F Argen-X

N/A

USD 29.24B
1AEA:F argenx SE

N/A

USD 29.18B
0QF:F Moderna Inc

N/A

USD 25.22B
22UA:F BioNTech SE

N/A

USD 19.33B

ETFs Containing DUL:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 42.21% 81% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.21% 81% B- 84% B
Trailing 12 Months  
Capital Gain 44.84% 81% B- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.84% 81% B- 81% B-
Trailing 5 Years  
Capital Gain 283.38% 88% B+ 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 283.38% 87% B+ 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 15.82% 81% B- 81% B-
Dividend Return 15.82% 81% B- 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.14% 62% D 45% F
Risk Adjusted Return 56.22% 91% A- 76% C+
Market Capitalization 27.60B 98% N/A 93% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.